This case expands the clinical phenotype of XMEA to include late adult-onset presentation, suggesting VMA21 sequencing for men with LAMP2-positive autophagic vacuolar myopathy.
Answers are grounded in this paper and cite their sources.
Extends XMEA phenotype to late adult onset; leaves open whether VMA21 sequencing is warranted in LAMP2-positive autophagic vacuolar myopathy.
INTRODUCTION: X-linked myopathy with excessive autophagy (XMEA) is characterized by autophagic vacuoles with sarcolemmal features. Mutations in VMA21 result in insufficient lysosome acidification, causing progressive proximal weakness with onset before age 20 years and loss of ambulation by middle age. METHODS: We describe a patient with onset of slowly progressive proximal weakness of the lower limbs after age 50, who maintains ambulation with the assistance of a cane at age 71. RESULTS: Muscle biopsy at age 66 showed complex muscle fiber splitting, internalized capillaries, and vacuolar changes characteristic of autophagic vacuolar myopathy. Vacuoles stained positive for sarcolemmal proteins, LAMP2, and complement C5b-9. Ultrastructural evaluation further revealed basal lamina reduplication and extensive autophagosome extrusion. Sanger sequencing identified a known pathologic splice site mutation in VMA21 (c.164-7T>G). CONCLUSIONS: This case expands the clinical phenotype of XMEA and suggests VMA21 sequencing be considered in evaluating men with LAMP2-positive autophagic vacuolar myopathy.
No takes yet. Share an insight, caveat, or question.
Crockett et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: